Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.23
+0.38 (3.21%)
At close: Feb 6, 2026, 4:00 PM EST
12.47
+0.24 (1.96%)
After-hours: Feb 6, 2026, 7:07 PM EST
Cullinan Therapeutics Employees
Cullinan Therapeutics had 111 employees as of December 31, 2024. The number of employees increased by 26 or 30.59% compared to the previous year.
Employees
111
Change (1Y)
26
Growth (1Y)
30.59%
Revenue / Employee
n/a
Profits / Employee
-$1,953,270
Market Cap
722.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | 24 | - | - | 24 | 0 |
| Sep 30, 2020 | 18 | - | - | 17 | 1 |
| Jun 30, 2020 | 17 | - | - | 16 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 837 |
| Gyre Therapeutics | 579 |
| KalVista Pharmaceuticals | 270 |
| Kura Oncology | 192 |
| Nektar Therapeutics | 61 |
| AgomAb Therapeutics NV | 58 |
| Arbutus Biopharma | 44 |
| Bright Minds Biosciences | 26 |
CGEM News
- 1 day ago - Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 9 days ago - Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers - Seeking Alpha
- 4 weeks ago - Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript - Seeking Alpha
- 2 months ago - Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - PRNewsWire
- 3 months ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting - GlobeNewsWire